Drug intelligence / Profile preview

Monovalent RSV Vaccine

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The Monovalent RSV Vaccine is a pharmaceutical vaccine developed by Sanofi Pasteur. It is administered as a suspension for intramuscular injection. This vaccine is designed to induce immunogenicity against the Respiratory Syncytial Virus (RSV) and is being investigated for its safety and immune response in adult participants aged 60 to 75 years.

Other names: Monovalent RSV Vaccine

Targets

RSV F (Respiratory syncytial virus fusion protein)M2-1 (Respiratory syncytial virus transcription antitermination factor M2-1)RSV N (Respiratory syncytial virus nucleoprotein)

Beyond the preview

Go deeper on Monovalent RSV Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Monovalent RSV Vaccine.

Explore the full profile